Hemolytic Uremic Syndrome News and Research

RSS

Acute renal failure in young children is most commonly linked to hemolytic uremic syndrome (HUS). In this situation, it often comes as a shock, occurring as it does in a child who was previously healthy but is now in mortal danger. This illness is caused by the toxin produced by certain bacterial strains, most commonly found in beef.

PCV-7 vaccine introduction leads to changing patterns of hemolytic uremic syndrome

Introduction of the PCV-7 vaccine to prevent invasive pneumococcal disease (IPD) has led to a shift in the types of bacteria causing hemolytic uremic syndrome (HUS)—an important cause of acute kidney failure in children, reports a study in the August issue of The Pediatric Infectious Disease Journal.

4 Aug 2010

Alexion second-quarter non-GAAP net income increases 56% to $36.9 million

Alexion Pharmaceuticals, Inc. today announced financial results for the three and six months ended June 30, 2010.

22 Jul 2010

Qualaquin for treatment of night time leg cramps leads to serious side effects, FDA warns

The U.S. Food and Drug Administration today warned that the unapproved use of the malaria drug Qualaquin (quinine sulfate) to treat night time leg cramps has resulted in serious side effects and prompted the manufacturer to develop a risk management plan aimed at educating health care professionals and patients about the potential risks.

9 Jul 2010

Alexion's Soliris may benefit patients with thrombotic microangiopathy from uncontrolled complement activation

Researchers reported today that Soliris® (eculizumab), a first-in-class terminal complement inhibitor developed by Alexion Pharmaceuticals, Inc., may provide clinical benefits to patients with thrombotic microangiopathy (TMA) resulting from uncontrolled complement activation. TMA, the formation of blood clots in capillaries and small arteries, can lead to life-threatening damage in multiple organs including kidney failure, thrombocytopenia (abnormally low platelet count) and anemia.

15 Jun 2010

Microbiologists identify potential target in cattle to prevent E. coli strain

Microbiologists at UT Southwestern Medical Center, working with the Department of Agriculture, have identified a potential target in cattle that could be exploited to help prevent outbreaks of food-borne illnesses caused by a nasty strain of Escherichia coli.

13 May 2010

FDA, CDC confirm connection between romaine lettuce and E.coli 0145 foodborne illness outbreak

The Food and Drug Administration (FDA), with the Centers for Disease Control and Prevention (CDC) and its state health partners have confirmed that the strain of E. coli O145 detected by the New York State Public Health Laboratory, Wadsworth Center, in Albany, in an unopened bag of shredded romaine lettuce distributed by Freshway Foods, matches the outbreak strain of E. coli O145.

11 May 2010

Newly updated informational website on E. coli

An outbreak of E. coli O145 in three states has hospitalized 12, three of whom have developed hemolytic Uremic syndrome, a severe complication of E. coli infection. Victims in Michigan, Ohio, and New York are ill with E. coli O145, which has been linked to a recall of tainted lettuce by Freshway Foods.

7 May 2010

Alexion Pharmaceuticals reports total revenues of $117.6M from net product sales of Soliris

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter ended March 31, 2010.

22 Apr 2010

Alexion Pharmaceuticals completes enrollment in Soliris clinical studies for aHUS

Alexion Pharmaceuticals, Inc. today announced that it has completed enrolling patients in all four previously announced prospective, open-label clinical studies investigating Soliris® (eculizumab) as a potential treatment for patients with atypical Hemolytic Uremic Syndrome (aHUS) being conducted in North America and multiple European countries.

21 Apr 2010

Rare Disease Day 2010: Alexion Pharmaceuticals joins NORD and EURORDIS to raise awareness

Alexion Pharmaceuticals, Inc., has joined the National Organization for Rare Disorders (NORD) and the European Organization for Rare Diseases (EURORDIS) in supporting the goals of the third annual Rare Disease Day, February 28, 2010.

26 Feb 2010

Alexion Pharmaceuticals announces financial results for quarter and year ended December 31, 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter and year ended December 31, 2009. For the three months ended December 31, 2009, Alexion Pharmaceuticals, Inc. ("Alexion" or, the "Company") reported net product sales of Soliris® (eculizumab) of $110.6 million, reflecting strong additions of new patients, compared to $77.4 million for the same period in 2008.

11 Feb 2010

Paralyzed dancer sues Cargill over E. coli tainted burger

Stephanie Smith, the twenty-two year old Minnesota dance instructor left paralyzed by a burger tainted with E. coli filed suit today against Cargill, who produced the contaminated meat. Ms. Smith, whose “The Burger that Shattered Her Life” profile in the New York Times was emailed all over the country, covered by hundreds of media outlets and galvanized legislators to change food laws, attempted mediation with the company, but was unable to come to a fair agreement with them.

5 Dec 2009

Data on Alexion Pharmaceuticals' Soliris to be presented at the ASH meeting

Alexion Pharmaceuticals, Inc. today announced that researchers are scheduled to present data relating to Soliris® (eculizumab) as a treatment for patients with paroxysmal nocturnal hemoglobinuria (PNH) during the 51st Annual Meeting of the American Society of Hematology (ASH), to be held December 5 – 8, 2009 at the Ernst N. Morial Convention Center in New Orleans.

11 Nov 2009

Pritzker Olsen to represent 3-year-old child sickened with an E. coli O157:H7 infection

Pritzker Olsen law firm has been retained to represent a 3-year-old child sickened with an E. coli O157:H7 infection and hemolytic uremic syndrome. The child is believed to have contracted the illness at a local apple orchard/ petting zoo in the Twin Cities (MN) area. Preliminary testing indicates that the genetic fingerprint of the E .coli O157:H7 obtained from the child’s stool sample matches the genetic fingerprint of E. coli from llama feces tested at the petting zoo.

26 Oct 2009

E. coli outbreak highlights the importance of food safety

Two students from Lincoln Middle School in Lincoln, Rhode Island were hospitalized several days after a field trip to Camp Bournedale in Plymouth, Massachusetts earlier this month. Several other students were also sickened.

24 Oct 2009

Alexion Pharmaceuticals reports increased revenues of 11% in third quarter 2009

Alexion Pharmaceuticals, Inc. today announced financial results for the quarter ended September 30, 2009.

22 Oct 2009

Effective steps to prevent the further spread of E. Coli outbreaks

News that a large and growing outbreak of highly toxic E. coli O157:H7 linked to the Gladstone Farm and Playbarn in Surrey, England has led E. coli expert Bill Marler to urge animal exhibitors on both sides of the Atlantic to implement existing safety guidelines.

16 Sep 2009

Soliris (Eculizumab) granted orphan drug designation in Europe and U.S. for atypical hemolytic uremic syndrome

Alexion Pharmaceuticals, Inc. has announced today that Soliris® (eculizumab), its first-in-class complement inhibitor, has been granted Orphan Medicinal Product Designation by the European Commission for the treatment of patients with atypical Hemolytic Uremic Syndrome (aHUS). AHUS is an ultra-rare, inherited, and life-threatening complement-inhibitor deficiency disease that often progresses to end-stage kidney disease or failure. The U.S. Food and Drug Administration granted orphan drug designation to Soliris for the same indication in May 2009. Soliris is not approved for the treatment of patients with aHUS.

6 Aug 2009

DuPont and USDA ARS to collaborate on new E. coli test in beef

DuPont and the United States Department of Agriculture (USDA) Agricultural Research Service (ARS) are teaming up to find new ways to detect an E. coli strain in beef that, even in low concentrations, can cause severe illness.

21 Feb 2008

Bioniche receives funding to scale-up E. coli O157:H7 vaccine production

Bioniche Life Sciences Inc. has announced that it has secured a $5 million commercial loan from the Business Development Bank of Canada (BDC) in support of the scale-up of vaccine production at its Belleville, Ontario facility.

8 Feb 2008